Clinical Trials /

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors

NCT03074513

Description:

This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Related Conditions:
  • Anal Canal Squamous Cell Carcinoma
  • Appendix Adenocarcinoma
  • Cervical Squamous Cell Carcinoma
  • Merkel Cell Carcinoma
  • Nasopharyngeal Carcinoma
  • Neuroendocrine Tumor
  • Peritoneal Mesothelioma
  • Pleural Mesothelioma
  • Squamous Cell Carcinoma of the Penis
  • Vaginal Squamous Cell Carcinoma
  • Vulvar Squamous Cell Carcinoma
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Atezolizumab and Bevacizumab in Rare Solid Tumors
  • Official Title: A Phase II, Single-Arm Open-Label Study Of The Combination Of Atezolizumab And Bevacizumab In Rare Solid Tumors

Clinical Trial IDs

  • ORG STUDY ID: 2016-0861
  • NCT ID: NCT03074513

Conditions

  • Malignant Neoplasms of Digestive Organs
  • Malignant Neoplasms of Lip Oral Cavity and Pharynx
  • Malignant Neoplasms of Mesothelial and Soft Tissue
  • Malignant Neoplasms of Respiratory and Intrathoracic Organs

Interventions

DrugSynonymsArms
AtezolizumabMPDL3280AAppendiceal Adenocarcinoma, KRAS-Wild Type
BevacizumabAvastin, Anti-VEGF monoclonal antibody, rhuMAb-VEGFAppendiceal Adenocarcinoma, KRAS-Wild Type

Purpose

The goal of this clinical research study is to learn if atezolizumab and bevacizumab can help to control rare solid tumors.

Detailed Description

Study Drug Administration:

Each cycle is 21 days.

On Day 1 of each cycle, participant will receive atezolizumab and bevacizumab by vein over about 60 minutes each.

Length of Treatment:

Participant may continue taking the study drugs for as long as the doctor thinks it is in participant's best interest. Participant will no longer be able to take the study drugs if the disease gets worse, if intolerable side effects occur, or if participant is unable to follow study directions.

Participation on the study will be over after the follow-up visits.

Study Visits:

On Day 1 of every odd-numbered cycle (Cycles 1, 3, 5, and so on):

- Participant will have a physical exam.

- Blood (about 4 teaspoons) will be drawn for routine tests and to learn if participant has certain genetic mutations (changes) that may affect participant's response to the study drugs.

- Urine will be collected for routine tests.

- During Cycle 3, blood (about 2 teaspoons) will be drawn before participant's dose of study drugs for biomarker testing.

- During Cycle 3, participant will have an image-guided core biopsy to check the status of the disease and for biomarker testing.

On Day 1 of every even-numbered cycle (Cycles 2, 4, 6, and so on):

- Participant will have a physical exam.

- Blood (about 4 teaspoons) will be drawn for routine testing.

- Participant will have an EKG. If the doctor thinks it is needed, participant will also have either an ECHO or MUGA scan.

Every 9-12 weeks, participant will have an MRI or CT scan.

At any time the doctor thinks it is needed, participant will have an EKG and either an ECHO or MUGA scan.

End-of-Treatment Visit:

About 30 days after participant's last dose of study drugs:

- Participant will have a physical exam.

- Blood (about 2 teaspoons) will be drawn for routine tests. If the disease got worse, this sample will also be used for biomarker testing.

- If the disease got worse, participant will have an image-guided core biopsy to check the status of the disease.

Follow-Up:

About every 3 months after participant's end-of-treatment visit, participant or participant's family/caregiver will be called by the study staff and asked how participant is doing. This call should last about 15 minutes. The study staff may also access your medical records or publically available records to learn about your long-term health status.

This is an investigational study. Atezolizumab is FDA approved and commercially available for the treatment of metastatic (has spread) non-small cell lung cancer (NSCLC).

Bevacizumab is FDA approved and commercially available for the treatment of metastatic colorectal cancer, metastatic non-squamous NSCLC, metastatic renal cell carcinoma, recurrent (has come back after treatment) glioblastoma, cervical cancer, and platinum-resistant (a type of chemotherapy) recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer.

The combination of these drugs to treat the type of cancer you have is considered investigational. The study doctor can explain how the study drugs are designed to work.

Up to 160 participants will be enrolled in this study. All will take part at MD Anderson.

Trial Arms

NameTypeDescriptionInterventions
Appendiceal Adenocarcinoma, KRAS-Wild TypeExperimentalParticipants receive Atezolizumab and Bevacizumab on Day 1 of each cycle. Each cycle is 21 days. Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest. About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
  • Atezolizumab
  • Bevacizumab
    Epstein-Barr Virus-Associated Nasopharyngeal CarcinomaExperimentalParticipants receive Atezolizumab and Bevacizumab on Day 1 of each cycle. Each cycle is 21 days. Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest. About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
    • Atezolizumab
    • Bevacizumab
      Human Papilloma Virus-Associated CancersExperimentalParticipants receive Atezolizumab and Bevacizumab on Day 1 of each cycle. Each cycle is 21 days. Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest. About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
      • Atezolizumab
      • Bevacizumab
        Merkel Cell CarcinomaExperimentalParticipants receive Atezolizumab and Bevacizumab on Day 1 of each cycle. Each cycle is 21 days. Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest. About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
        • Atezolizumab
        • Bevacizumab
          Neuroendocrine Tumors, PancreaticExperimentalParticipants receive Atezolizumab and Bevacizumab on Day 1 of each cycle. Each cycle is 21 days. Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest. About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
          • Atezolizumab
          • Bevacizumab
            Neuroendocrine Tumors, ExtrapancreaticExperimentalParticipants receive Atezolizumab and Bevacizumab on Day 1 of each cycle. Each cycle is 21 days. Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest. About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
            • Atezolizumab
            • Bevacizumab
              Peritoneal MesotheliomaExperimentalParticipants receive Atezolizumab and Bevacizumab on Day 1 of each cycle. Each cycle is 21 days. Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest. About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
              • Atezolizumab
              • Bevacizumab
                Pleural MesotheliomaExperimentalParticipants receive Atezolizumab and Bevacizumab on Day 1 of each cycle. Each cycle is 21 days. Participant may continue taking the study drugs for as long as the doctor thinks it is in their best interest. About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
                • Atezolizumab
                • Bevacizumab

                  Eligibility Criteria

                  Inclusion Criteria:

                  1. Signed Informed Consent Form

                  2. Age >/= 18 years

                  3. Ability to comply with the study protocol, in the investigator's judgment

                  4. Measurable disease according to RECIST v1.1. Previously irradiated lesions can be considered as measurable disease only if progressive disease has been unequivocally documented at that site since radiation.

                  5. ECOG Performance Status of 0 or 1

                  6. Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment: ANC >/= 1.5 x 10(9)/L without granulocyte colony-stimulating factor support; Lymphocyte count >/= 0.5 x 10(9)/L; Platelet count >/= 100 x 10(9)/L without transfusion; WBC Count >/= 2500/ul; Hemoglobin >/= 90 g/L [Patients may be transfused to meet this criterion]; AST, ALT, and alkaline phosphatase (ALP) </= 2.5 x upper limit of normal (ULN), with the following exceptions: Patients with documented liver metastases: AST and ALT </= 5 x ULN Patients with documented liver or bone metastases: ALP </= 5 x ULN - Serum bilirubin ≤ 1.5 x ULN - Serum creatinine </= 1.5 x ULN - Serum albumin >/= 2.5 g/dL - For patients not receiving therapeutic anticoagulation: INR or aPTT </= 1.5 x ULN

                  7. For patients receiving therapeutic anticoagulation: stable anticoagulant regimen

                  8. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use a contraceptive method with a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of study treatment.

                  9. (cont.) A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (>/= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus). Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

                  10. Appendiceal adenocarcinoma basket

                  1. Metastatic appendiceal adenocarcinoma

                  2. Not considered candidate for curative surgery

                  11. Epstein-Barr Virus-associated nasopharyngeal carcinoma basket a. Metastatic or locally recurrent disease not amenable to curative intent treatment b. EBV positive by EBV encoded small RNA in situ hybridization (EBER ISH) c. Any number of prior therapies, including 0

                  12. Human Papilloma Virus-associated cancer basket

                  1. Histologically proven squamous carcinoma of the anal canal, penile, vaginal, vulva, or refractory cervical cancer will be enrolled.

                  2. Patients must have metastatic disease not amenable to surgical resection.

                  3. If HIV+ positive, all patients infected with Human Immunodeficiency Virus (HIV) may be eligible for study. d. Patients co-infected with hepatitis B virus and/or hepatitis C virus may be included in this study provided that their liver function tests remain within the limits listed above. Patients must be followed by a hepatologist during the course of this study.

                  13. Merkel Cell Carcinoma basket a. Metastatic or locally recurrent disease not amenable to curative intent treatment b. Any number of prior therapies, including 0

                  14. Neuroendocrine tumors, pancreatic basket

                  1. Grade 1 or grade 2 according to reviewing pathologist

                  2. Progressive disease over the preceding 12 months

                  3. Any number of prior therapies, including 0

                  4. Patients using a somatostatin analogue for symptom control must be on stable doses for 56 days prior to enrollment.

                  15. Neuroendocrine tumors, extrapancreatic basket

                  1. Grade 1 or grade 2 according to reviewing pathologist

                  2. Progressive disease over the preceding 12 months

                  3. Any number of prior therapies, including 0

                  4. Patients using a somatostatin analogue for symptom control must be on stable doses for 56 days prior to enrollment.

                  16. Peritoneal mesothelioma basket a. Refractory to platinum and pemetrexed systemic therapy b. Any number of prior therapies

                  17. Pleural mesothelioma basket

                  1. Metastatic or locally recurrent disease not amenable to curative intent treatment

                  2. Refractory to platinum and pemetrexed systemic therapy

                  3. Any number of prior therapies

                  Exclusion Criteria:

                  1. Treatment for the studied cancer within 28 days prior to initiation of study treatment

                  2. Treatment with investigational therapy within 28 days prior to initiation of study treatment

                  3. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

                  4. Known hypersensitivity to biopharmaceutical agents produced in Chinese hamster ovary cells

                  5. Known allergy or hypersensitivity to any component of the atezolizumab formulation

                  6. Known allergy or hypersensitivity to any component of the bevacizumab formulation

                  7. Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, or multiple sclerosis, with the following exceptions:

                  8. (cont.) Patients with a history of autoimmune-related hypothyroidism who are on thyroid replacement hormone are eligible for the study.

                  Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen are eligible for the study.

                  Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

                  - Rash must cover < 10% of body surface area

                  - Disease is well controlled at baseline and requires only low-potency topical corticosteroids

                  - No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months

                  9. Prior allogeneic stem cell or solid organ transplantation

                  10. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan.

                  (History of radiation pneumonitis in the radiation field (fibrosis) is permitted)

                  11. Positive HIV test at screening (except in cohort 3, HPV-associated cancers)

                  12. Except in cohort 3, HPV-associated cancers, active hepatitis B virus (HBV) infection (chronic or acute), defined as having a positive hepatitis B surface antigen (HBsAg) test at screening. Patients with a past or resolved HBV infection, defined as having a negative HBsAg test and a positive total hepatitis B core antibody (HBcAb) test and negative HBV DNA test at screening, are eligible for the study.

                  13. Except in cohort 3, HPV-associated cancers active hepatitis C virus (HCV) infection, defined as having a positive HCV antibody test followed by a positive HCV RNA test at screening.

                  The HCV RNA test will be performed only for patients who have a positive HCV antibody test.

                  14. Active tuberculosis

                  15. Severe infection within 4 weeks prior to initiation of study treatment, including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia

                  16. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment.

                  Patients receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.

                  17. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction, or cerebrovascular accident within 3 months prior to initiation of study treatment, unstable arrhythmia, or unstable angina

                  18. Major surgical procedure other than for diagnosis within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study

                  19. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during the course of the study, or up to 5 months following the anticipated last dose of atezolizumab.

                  20. Malignancies other than the disease under study within 5 years prior to Cycle 1, Day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome (such as adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, or ductal carcinoma in situ treated surgically with curative intent) or undergoing active surveillance per standard-of-care management (e.g., chronic lymphocytic leukemia Rai Stage 0)

                  21. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an investigational drug, may affect the interpretation of the results, or may render the patient at high risk from treatment complications

                  22. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies

                  23. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 [IL-2]) within 4 weeks or five half-lives of the drug (whichever is longer) prior to initiation of study treatment

                  24. Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study, with the following exceptions:

                  Patients who received low-dose immunosuppressant medication are eligible for the study.

                  Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.

                  25. Pregnant or breastfeeding, or intending to become pregnant during the study. Women of childbearing potential must have a negative serum pregnancy test result within 14 days prior to initiation of study treatment.

                  26. Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg).

                  Anti-hypertensive therapy to maintain a systolic blood pressure <150 mmHg and/or diastolic blood pressure < 100 mmHg is permitted.

                  27. Prior history of hypertensive crisis or hypertensive encephalopathy

                  28. History of stroke or transient ischemic attack within 6 months prior to Cycle 1, Day 1

                  29. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1

                  30. Patients with a baseline ECG demonstrating a QTc > 460 ms

                  31. Evidence of bleeding diathesis or clinically significant coagulopathy (in the absence of therapeutic anticoagulation)

                  32. Current or recent (within 10 calendar days prior to Cycle 1, Day 1) use of dipyramidole, ticlopidine, clopidogrel, or cilostazol

                  33. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 calendar days prior to the first dose of bevacizumab

                  34. History of abdominal or tracheoesophageal fistula or gastrointestinal perforation within 6 months prior to Cycle 1, Day 1

                  35. Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding

                  36. Evidence of abdominal free air not explained by paracentesis or recent surgical procedure

                  37. Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture

                  38. Proteinuria, as demonstrated by urine dipstick or > 1.0 g of protein in a 24-hour urine collection. All patients with >/= 2+ protein on dipstick urinalysis at baseline must undergo a 24-hour urine collection for protein.

                  39. Appendiceal adenocarcinoma basket

                  1. Complete or partial bowel obstruction

                  40. Epstein-Barr Virus-associated nasopharyngeal carcinoma basket.

                  41. Human Papilloma Virus-associated cancers basket

                  a. None

                  42. Merkel Cell Carcinoma basket

                  a. none

                  43. Neuroendocrine tumors, pancreatic basket

                  1. Grade 3, poorly differentiated neuroendocrine carcinoma

                  2. Large cell or small cell histology

                  44. Neuroendocrine tumors, extrapancreatic basket

                  1. Grade 3, poorly differentiated neuroendocrine carcinoma

                  2. Large cell or small cell histology

                  45. Peritoneal mesothelioma basket

                  a. None

                  46. Pleural mesothelioma basket a. None

                  Maximum Eligible Age:N/A
                  Minimum Eligible Age:18 Years
                  Eligible Gender:All
                  Healthy Volunteers:No

                  Primary Outcome Measures

                  Measure:Overall Response Rate of Atezolizumab in Combination with Bevacizumab
                  Time Frame:12 weeks
                  Safety Issue:
                  Description:Response determined by an independent radiologist according to RECIST v1.1.

                  Secondary Outcome Measures

                  Measure:Adverse Events of Atezolizumab in Combination with Bevacizumab
                  Time Frame:6 months
                  Safety Issue:
                  Description:Occurrence and severity of adverse events, with severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0.

                  Details

                  Phase:Phase 2
                  Primary Purpose:Interventional
                  Overall Status:Not yet recruiting
                  Lead Sponsor:M.D. Anderson Cancer Center

                  Trial Keywords

                  • Malignant neoplasms of digestive organs
                  • Malignant neoplasms of lip oral cavity and pharynx
                  • Malignant neoplasms of mesothelial and soft tissue
                  • Malignant neoplasms of respiratory and intrathoracic organs
                  • Rare Solid Tumors
                  • Atezolizumab
                  • MPDL3280A
                  • Bevacizumab
                  • Avastin
                  • Anti-VEGF monoclonal antibody
                  • rhuMAb-VEGF
                  • Phone call

                  Last Updated

                  March 3, 2017